Posted by Michael Wonder on 28 Nov 2019
Sosei Heptares announces that the COPD treatment Ultibro Breezhaler has been included in the National Reimbursement Drug List in China
28 November 2019 - Sosei Group announces that Ultibro Breezhaler (an inhaled once-daily fixed-dose combination of indacaterol/glycopyrronium bromide) has been included in the 2019 National Reimbursement Drug List in China for the treatment of chronic obstructive pulmonary disease.
The product was launched in China in March 2019, along with related product Seebri Breezhaler and both are approved for use in over 100 countries worldwide, including countries within the EU and Latin America, Japan, Canada, Switzerland and Australia.
